# US 2020/0390712 A1 · Method to produce a medicinal product comprising a biologically active protein and the resulting product

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390712 A1
- Document ID: US20200390712A1
- Status: Published application
- Kind: A1
- Application number: 16/918,611
- Filed: 2020-07-01
- Published: 2020-12-17
- Earliest claimed: 2012-07-10
- Assignees: Intervet Inc.
- Applicants: Intervet Inc.
- Inventors: Kevin O'Connell; Sandhya Buchanan
- Web page: https://patentgrep.com/patent/US20200390712A1

## CPC

- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 39/155: Paramyxoviridae, e.g. parainfluenza virus
- A61K 39/175: Canine distemper virus
- A61K 39/235: Adenoviridae
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K 2039/5254: {avirulent or attenuated}
- C12N 2710/10334: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18434: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/18711: Rubulavirus, e.g. mumps virus, parainfluenza 2,4
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method.

## Claims

### Claim 1

A method for producing a medicinal product comprising a biologically active protein comprising the steps of:
providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar,
freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form,
putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements,
reducing the pressure in the drying apparatus below atmospheric pressure,
providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body; wherein the biologically active protein is dispersed in a solid matrix of the non-polymeric sugar; and wherein the body is a spheroid that has a volume equal to or above 50 μl.

### Claim 2 (depends on 1)

The method of claim 1, wherein the frozen solvent is sublimated in less than 48 hours.

### Claim 3 (depends on 2)

The method of claim 2, wherein the frozen solvent is sublimated in less than 36 hours.

### Claim 4 (depends on 3)

The method of claim 3, wherein the frozen solvent is sublimated in 16 to 24 hours.

### Claim 5 (depends on 1)

The method of claim 1 wherein at most 20% of the surface of the body is contiguous with the one or more restraining elements of the support.

### Claim 6 (depends on 5)

The method of claim 5, wherein at most 10% of the surface of the body is contiguous with the one or more restraining elements of the support.

### Claim 7 (depends on 1)

The method of claim 1, wherein the frozen body is a spheroid.

### Claim 8 (depends on 7)

The method of claim 7, wherein the spheroid has a volume between 50 μl and 1000 μl.

### Claim 9 (depends on 1)

The method of claim 1, wherein the restraining element of the support is a floor, the body being provided lying on this floor, and the support is open to allow radiation to freely pass to the said floor, characterised in that at least a part of the heat is provided by emitting heat radiation from a radiation source present in the drying apparatus above the support, to reach the frozen body.

### Claim 10 (depends on 1)

The method of claim 1, wherein at least a part of the heat is provided by conduction of heat via the restraining element that is contiguous with the frozen body.

### Claim 11 (depends on 1)

The method of claim 1, wherein the restraining element of the support is a floor, the body being provided lying on this floor, and the support is open to allow radiation to freely pass to the said floor, characterised in that the heat is provided by emitting heat radiation from a radiation source present in the drying apparatus above the support to reach the body in combination with conduction of heat via the restraining element that is contiguous with the frozen body.

### Claim 12 (depends on 1)

The method of claim 1, wherein the amount of the sugar in the aqueous composition is chosen from the group that consists of the ranges 20-55% w/w, 20-50% w/w, 20-45% w/w, 25-45% w/w, 25-40% w/w, 25-35% w/w and 27-30% w/w.

### Claim 13 (depends on 12)

The method of claim 12, wherein the sugar comprises monomeric and/or dimeric molecules.

### Claim 14 (depends on 13)

The method of claim 13, wherein the sugar comprises glucose, galactose, maltose, sucrose, trehalose, fructose, lactose, saccharose, mannitol, sorbitol and/or xylitol.

### Claim 15 (depends on 1)

The method of claim 1, wherein the restraining element of the support is a floor, characterised in that multiple frozen bodies are positioned in the form of a monolayer on said floor while being dried.

### Claim 16 (depends on 1)

The method of claim 1, wherein a residual moisture content in the dried body is less than 2% w/w.

### Claim 17

A medicinal product in the form of a substantial homogenous freeze-dried body having a volume between 50 and 1000 μl comprising a biologically active protein, the protein being dispersed in a solid matrix of a non-polymeric sugar, wherein the body comprises between about 21 and 72% w/v of the said sugar.

### Claim 18 (depends on 17)

The body of claim 17, wherein the body is a spheroid.

### Claim 19 (depends on 8)

A product in the form of a substantial homogenous freeze-dried body having a volume between 50 and 1000 μl, comprising a biologically active protein, the body being obtainable via the method of claim 8.

### Claim 20 (depends on 14)

The method of claim 14, wherein a residual moisture content in the dried body is less than 2% w/w.
